Lapelga (pegfilgrastim)

pCPA File Number: 22352

Negotiation Status:

Concluded with an LOI

Indication(s):

To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.

Sponsor/Manufacturer:

Apobiologix, a Division of Apotex Inc.

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2023-05-19

Negotiation Process Concluded:

2023-08-03